Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sputnik V's efficacy against infection with the Delta variant is 83% and 94% against hospitalization. To date Sputnik V has been registered in 70 countries in various parts of the world with total population of over 4 billion people.
Product Name : AZD1222
Product Type : Vaccine
Upfront Cash : Inapplicable
October 21, 2021
Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RDIF and ChemRar Launch Final Stage of Favipiravir Clinical Trial
Details : RDIF and ChemRar have applied to the Russian Ministry of Health for the accelerated registration of Favipiravir in accordance with the Russian Government's Decree.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable